Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 301–400 of 3,704
Krumholz, H. M., de Lemos, J. A., Sattar, N., Linetzky, B., Sharma, P., Mast, C. J., Ahmad, N. N., Bunck, M. C., & Stefanski, A. (2024) · Heart · doi:10.1136/heartjnl-2024-324170 · Cited by 54
Self-citationCohen, R. V., Busetto, L., Levinson, R., Le Roux, C. W., Salminen, P., Prager, G., Surgery, I. C. O. T. R. O. O. M. M. I. T. C. O. M. B., Aminian, A., Blüher, M., Carlsson, L., et al. (2024) · British Journal of Surgery · doi:10.1093/bjs/znae283 · Cited by 52
Kanbour, S., Ageeb, R. A., Malik, R. A., & Abu-Raddad, L. J. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00346-2 · Cited by 79
Gudzune, K. A., Stefanski, A., Cao, D., Mojdami, D., Wang, F., Ahmad, N., & Ling Poon, J. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16046 · Cited by 51
Self-citationGLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms
Mullur, N., Morissette, A., Morrow, N. M., & Mulvihill, E. E. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0046 · Cited by 51
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths
Scirica, B. M., Lincoff, A. M., Lingvay, I., Bogdanski, P., Buscemi, S., Colhoun, H., Craciun, A.-E., Ezhov, M., Hardt-Lindberg, S., Kleist Jeppesen, O., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.007 · Cited by 51
Update on Obesity and Cardiovascular Risk: From Pathophysiology to Clinical Management
Gallo, G., Desideri, G., & Savoia, C. (2024) · Nutrients · doi:10.3390/nu16162781 · Cited by 75
“Tirzepatide also induces a delay of gastric emptying, reduces fasting and postprandial glucose concentration, and decreases food intake, with sustained weight reduction in obese adults [118].”
BackgroundObesity pharmacotherapy in older adults: a narrative review of evidence
Henney, A. E., Wilding, J. P. H., Alam, U., & Cuthbertson, D. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01529-z · Cited by 51
“In total, 85%, 89%, and 91% of participants lost 5% bodyweight with 5, 10, and 15 mg of tirzepatide, respectively (vs. 35% with placebo) [102].”
MASLD treatment—a shift in the paradigm is imminent
Machado, M. V. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1316284 · Cited by 51
“The oldest generation of anti-obesity drugs could achieve a very mild weight loss of 3 to 8% (84).”
BackgroundResultHerrou, J., Mabilleau, G., Lecerf, J.-M., Thomas, T., Biver, E., & Paccou, J. (2023) · Calcified Tissue International · doi:10.1007/s00223-023-01150-8 · Cited by 50
“As shown in Table 1, several drugs are under investigation for weight loss management in PwO with various mechanism of action [22–25].”
Hormonal Gut–Brain Signaling for the Treatment of Obesity
Roh, E., & Choi, K. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043384 · Cited by 66
“The SURMOUNT-1 trial is the first clinical trial to test the ability of tirzepatide to induce weight loss in overweight or obese patients [25].”
BackgroundUse and Misuse of BMI Categories
Flegal, K. M. (2023) · The AMA Journal of Ethic · doi:10.1001/amajethics.2023.550 · Cited by 71
A narrative review of approved and emerging anti-obesity medications
Abdi Beshir, S., Ahmed Elnour, A., Soorya, A., Parveen Mohamed, A., Sir Loon Goh, S., Hussain, N., Al Haddad, A. H. I., Hussain, F., Yousif Khidir, I., & Abdelnassir, Z. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.101757 · Cited by 51
Gutgesell, R. M., Khalil, A., Liśkiewicz, A., Maity‐Kumar, G., Novikoff, A., Grandl, G., Liśkiewicz, D., Coupland, C., Karaoglu, E., Akindehin, S., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01294-x · Cited by 62
Muse, E. D., & Topol, E. J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.02.002 · Cited by 50
Pancreatic polypeptide revisited: Potential therapeutic effects in obesity-diabetes
Zhu, W., Tanday, N., Flatt, P. R., & Irwin, N. (2022) · Peptides · doi:10.1016/j.peptides.2022.170923 · Cited by 58
Zaffina, I., Pelle, M. C., Armentaro, G., Giofrè, F., Cassano, V., Sciacqua, A., & Arturi, F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1095753 · Cited by 56
“However, a recent study has shown that a dual GLP-1 and GIP receptor agonist achieves better glycemic control, insulin sensitivity, lipid metabolism, and body weight reduction (14) compared to either treatment alone.”
BackgroundBeyond glycemia: Comparing tirzepatide to GLP-1 analogues
Andraos, J., Muhar, H. K., & Smith, S. R. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09825-1 · Cited by 59
“Adverse effects are similar in patients using the medication for diabetes to those using the medication for weight loss [67].”
BackgroundCai, W., Zhang, R., Yao, Y., Wu, Q., & Zhang, J. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1277113 · Cited by 67
“Finally, 12 articles were included (23, 26–35).”
BackgroundMethodResultInfluentialTreatment of OSA and its Impact on Cardiovascular Disease, Part 2
Javaheri, S., Javaheri, S., Gozal, D., Campos‐Rodríguez, F., Martínez‐García, M. Á., Mokhlesi, B., Mehra, R., McNicholas, W. T., Somers, V. K., Zee, P. C., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.07.024 · Cited by 54
Kadowaki, T., Kiyosue, A., Shingaki, T., Oura, T., & Yokote, K. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00377-2 · Cited by 49
Self-citationJanež, A., Muzurović, E. M., Bogdański, P., Czupryniak, L., Fábryová, Ľ., Fras, Z., Guja, C., Haluzík, M., Kempler, P., Lalic, N. M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01615-5 · Cited by 70
“The results of large‑scale trials (e.g. SUR‑ PASS‑3, SURMOUNT‑1) indicated that the use of dual GLP‑1/GIP agonist tirzepatide provided greater BW loss benefits in patients with obe‑ sity with/without T2D compared with GLP‑1 RAs [166, 167].”
BackgroundGasoyan, H., Butsch, W. S., Schulte, R., Casacchia, N. J., Le, P., Boyer, C. B., Griebeler, M. L., Burguera, B., & Rothberg, M. B. (2025) · Obesity · doi:10.1002/oby.24331 · Cited by 54
“…lower than that observed in the main phase 3 trials of semaglutide 2.4 mg (STEP 1) and tirzepatide 5 to 15 mg (SURMOUNT-1), in which 14.9% and 15.0% and 20.9% weight reduction, respectively, was demonstrated in patients with overweight or obesity (without T2D) plus a lifestyle intervention [3, 4].”
InfluentialDPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
Razavi, M. A., Wei, Y., Rao, X., & Zhong, J. (2022) · Military Medical Research · doi:10.1186/s40779-022-00410-2 · Cited by 58
“9% in adults with body fat mass of 30 or more after 72-week follow-up [22].”
BackgroundKennedy, C., Hayes, P. C., Salama, S., Hennessy, M., & Fogacci, F. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030772 · Cited by 52
“Of interest is the recently published SURMOUNT1 trial that assessed weight reduction for patients without diabetes with tirzepatide, a dual GLP-1 and GIP receptor agonist [30].”
Lee, H. A., & Kim, H. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119324 · Cited by 48
Quarenghi, M., Capelli, S., Galligani, G., Giana, A., Preatoni, G., & Quarenghi, R. T. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113791 · Cited by 67
“…studies have shown that mean total weight loss is approximately 30% after one year of bariatric surgery, 31% for Roux-en-Y gastric bypass (RYGB), 25% for sleeve gastrectomy, compared to only a mere 6% to 20% of total weight loss in patients undergoing an annual treatment with GLP1-RA [29,38,60,61].”
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 160
Incretin-based therapies for the treatment of obesity-related diseases
Caruso, I., Cignarelli, A., Sorice, G. P., Perrini, S., & Giorgino, F. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00030-5 · Cited by 48
“Across the SURMOUNT trials, the proportion of patients losing >5%, 10%, 15% and 20% of body weight was 79.2 – 97.3%, 60.5 – 92.1%, 39.7 – 84.1%, and 21.5 – 69.5%, respectively 34 – 37 ; notably, 9.0 – 54.5% of patients lost >25% of initial body weight 36 (Fig.”
InfluentialDubin, R. L., Heymsfield, S. B., Ravussin, E., & Greenway, F. L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15913 · Cited by 47
Zafer, M., Tavaglione, F., Romero‐Gómez, M., & Loomba, R. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70196 · Cited by 47
Xie, Z., Hu, J., Gu, H., Li, M., & Chen, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1244432 · Cited by 47
“9 kg) over 72 weeks of treatment, suggesting that tirzepatide 15mg is also a potential weight loss agent (56).”
BackgroundSztanek, F., Tóth, L. I., Pető, A., Hernyák, M., Diószegi, Á., & Harangi, M. (2024) · Biomedicines · doi:10.3390/biomedicines12061320 · Cited by 47
“In the SURMOUNT-1 and -3 studies, tirzepatide administered at a high dose of 15 mg subcutaneously once weekly resulted in approximately a 20% reduction in body weight in overweight and obese, non-diabetic adults, even after up to 2 years of treatment [84,85].”
BackgroundMelson, E., Miras, A. D., & Papamargaritis, D. (2023) · Clinical Medicine · doi:10.7861/clinmed.2023-0144 · Cited by 46
Mayfield, C. K., Mont, M. A., Lieberman, J. R., & Heckmann, N. D. (2023) · The Journal of Arthroplasty · doi:10.1016/j.arth.2023.07.017 · Cited by 47
Approach the Patient With Obstructive Sleep Apnea and Obesity
Meyer, E. J., & Wittert, G. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad572 · Cited by 66
Reijnders, E., van der Laarse, A., Jukema, J. W., & Cobbaert, C. M. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1264319 · Cited by 61
The Kidney in Obesity: Current Evidence, Perspectives and Controversies
Kounatidis, D. C., Vallianou, N. G., Stratigou, T., Voukali, M., Karampela, Ι., & Dalamaga, Μ. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00583-y · Cited by 57
Obesity-related Asthma: A Pathobiology-based Overview of Existing and Emerging Treatment Approaches
Althoff, M. D., Gaietto, K. M., Holguín, F., & Forno, E. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202406-1166so · Cited by 67
Panganiban, J. A., Kehar, M., Ibrahim, S. H., Hartmann, P., Sood, S., Hassan, S. M., Ramirez, C. M., Kohli, R., Censani, M., Mauney, E. E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100164 · Cited by 73
“Retatrutide , a triple glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors agonists, has led to substantial body weight reduction with indirect implications of improvement in MASLD parameters [148].”
Coskun, T., Wu, Q., Schloot, N. C., Haupt, A., Milicevic, Z., Khouli, C., & Harris, C. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00092-0 · Cited by 57
Friedrichsen, M. H., Endahl, L., Kreiner, F. F., Goldwater, R., Kankam, M., Toubro, S., & Nygård, S. B. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101801 · Cited by 46
“Enhanced weight loss may be achieved through co-agonism; dual agonism at the GLP-1 and gastric inhibitory polypeptide (GIP) receptors with tirzepatide has demonstrated mean weight loss of up to 19% [17].”
BackgroundGolovaty, I., Ritchie, N. D., Tuomilehto, J. O., Mohan, V., Ali, M. K., Gregg, E. W., Bergman, M., & Moin, T. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110195 · Cited by 59
Müllertz, A. L. O., Sandsdal, R. M., Jensen, S. B. K., & Torekov, S. S. (2024) · Obesity Reviews · doi:10.1111/obr.13717 · Cited by 46
“The included studies were all phase 3 randomized controlled trials investigating either the effect of subcutaneous semaglutide (five studies 29,42,43,55,56 ) or tirzepatide (two studies 57,58 ).”
BackgroundInfluentialUnderstanding the complex macrophage landscape in MASLD
Ponti, F. F. D., Liu, Z., & Scott, C. L. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101196 · Cited by 72
“…been approved for the treatment of MASLD 37 and while glucagon-like peptide-1 receptor agonists, including semaglutide, tirzepatide, and liraglutide have also shown encouraging results in recent clinical trials for the treatment of MASLD, 38 – 41 their approval for this indication is still pending.”
NK2R control of energy expenditure and feeding to treat metabolic diseases
Sass, F., Ma, T., Ekberg, J. H., Kirigiti, M. A., García‐Ureña, M., Dollet, L., Brown, J. M., Basse, A. L., Yacawych, W. T., Burm, H. B., et al. (2024) · Nature · doi:10.1038/s41586-024-08207-0 · Cited by 53
Early-onset colorectal cancer as an emerging disease of metabolic dysregulation
Du, M., Drew, D. A., Goncalves, M. D., Cao, Y., & Chan, A. T. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01159-z · Cited by 66
“Of note, metformin induces only modest weight loss and insulin suppression in comparison with GLP1RAs 172,173 .”
Jakubowska, A., Roux, C. W. L., & Viljoen, A. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1942 · Cited by 45
“The technology rapidly progressed with several types of co-agonists forging ahead in clinical trials including GIP/GLP-1 receptor dual agonists with one of the most notable being tirzepatide [8,9].”
BackgroundMethodInfluentialPharmacologic Treatment of Obesity in Reproductive Aged Women
Nuako, A. A., Tu, L., Reyes, K. J. C., Chhabria, S. M., & Stanford, F. C. (2023) · Current Obstetrics and Gynecology Reports · doi:10.1007/s13669-023-00350-1 · Cited by 67
Bone health in adults with obesity before and after interventions to promote weight loss
Paccou, J., & Compston, J. E. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00163-3 · Cited by 55
Savarese, G., Schiattarella, G. G., Lindberg, F., Anker, M. S., Bayés‐Genís, A., Bäck, M., Braunschweig, F., Bucciarelli‐Ducci, C., Butler, J., Cannata, A. N., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3676 · Cited by 58
Hurtado, I., Robles, C., Peiró, S., García-Sempere, A., & Sanfélix-Gimeno, G. (2024) · Diabetologia · doi:10.1007/s00125-024-06243-z · Cited by 45
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y. (2023) · Molecules · doi:10.3390/molecules28020751 · Cited by 44
“Tirzepatide Mounjaro / SC, qw T2DM Obesity 2022 2022 FTD 2 [90,91] [86] CT-868 / SC, qd T2DM Phase 1 / NNC0090-2746 (RG7697) / SC, qd T2DM Phase 2 [92] GLP-1R/GLP-2R Dapiglutide (ZP7570) / SC, qw SBS Phase 1 / GLP-1R/GCGR”
BackgroundThe future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
Andreasen, C. R., Andersen, A., & Vilsbøll, T. (2023) · Diabetologia · doi:10.1007/s00125-023-05966-9 · Cited by 44
Huang, Y., Liao, W., Huang, J., Lin, Y., Yang, S., Huang, C., Wang, C., & Su, P. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15869 · Cited by 44
Early-onset atherosclerotic cardiovascular disease
Mousavi, I., Suffredini, J. M., Virani, S. S., Ballantyne, C. M., Michos, E. D., Misra, A., Saeed, A., & Jia, X. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae240 · Cited by 62
The Ambiguous Correlation of Blautia with Obesity: A Systematic Review
Chanda, W., Jiang, H., & Liu, S. (2024) · Microorganisms · doi:10.3390/microorganisms12091768 · Cited by 51
Sanchez-Garrido, M. A., Serrano-López, V., Ruíz-Pino, F., Vazquez, M. J., Rodríguez-Martín, A., Torres, E., Velasco, I., Rodríguez, A., Chicano‐Gálvez, E., Mora-Ortiz, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52898-y · Cited by 60
“…our HOMA-IR data document a globally moderate but detectable improvement in insulin resistance in mice treated with metformin; further, these new HOMA-IR data further attested for the beneficial effects of the multi-agonists, and particularly of the GLP1/estrogen conjugate, on insulin resistance.”
Carbone, F., Després, J., Ioannidis, J. P. A., Neeland, I. J., Garruti, G., Busetto, L., Liberale, L., Ministrini, S., Vilahur, G., Schindler, T. H., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70059 · Cited by 57
Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity
Lin, H.-T., Tsai, Y.-F., Liao, P.-L., & Wei, J. C.-C. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.21016 · Cited by 43
Hall, K. D. (2024) · Obesity · doi:10.1002/oby.24027 · Cited by 43
“…simulations were initialized using mean base-line anthropometric data from published studies on intensive calorie restriction [7], dietary macronutrient restriction [8], RYGB surgery [9], semaglutide [2], and tirzepatide [1] assuming a mean baseline free-living physical activity level of 1.65 [10].”
BackgroundMethodInfluentialHankosky, E. R., Wang, H., Neff, L. M., Kan, H., Wang, F., Ahmad, N. N., Stefanski, A., & Garvey, W. T. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15269 · Cited by 44
“27 In a network meta-analysis, tirzepatide resulted in significantly greater weight reduction compared with semaglutide and liraglutide among people with obesity without T2D.”
BackgroundMethodResultInfluentialSelf-citationAnson, M., Henney, A. E., Broadwell, N., Zhao, S. S., Ibarburu, G. H., Lip, G. Y. H., Wilding, J. P. H., Cuthbertson, D. J., & Alam, U. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102777 · Cited by 44
“16,17 To address these limitations, we explored the impact of tirzepatide, compared with semaglutide, on the incidence of T2D, in a large secondary care cohort.”
BackgroundMetabolic Messengers: glucagon
MacDonald, P. E., & Rorsman, P. (2023) · Nature Metabolism · doi:10.1038/s42255-022-00725-3 · Cited by 43
Pharmacological Support for the Treatment of Obesity—Present and Future
Kosmalski, M., Deska, K., Bąk, B., Różycka-Kosmalska, M., & Pietras, T. (2023) · Healthcare · doi:10.3390/healthcare11030433 · Cited by 68
Why does type 2 diabetes mellitus impair weight reduction in patients with obesity? A review
Bays, H. E. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100076 · Cited by 63
“…SURMOUNT program [21], SURMOUNT 1 demonstrated weight reduction up to 21% among patients with overweight/obesity and without diabetes mellitus [22], while preliminary reports suggest that in SURMOUNT 2, tirzepatide reduced weight up to 16% among patients with overweight/obesity and type 2…”
BackgroundDietary and metabolic effects on intestinal stem cells in health and disease
Shay, J. E. S., & Yilmaz, Ö. H. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00980-7 · Cited by 64
Obesity and Cardiovascular Risk: Systematic Intervention Is the Key for Prevention
Perone, F., Pingitore, A., Conte, E., Hálasz, G., Ambrosetti, M., Peruzzi, M., & Cavarretta, E. (2023) · Healthcare · doi:10.3390/healthcare11060902 · Cited by 57
“The efficacy and safety of Tirzepatide in body weight reduction was investigated in a recent clinical, randomized trial [66].”
BackgroundFiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity
Hwang, J. H., Laiteerapong, N., Huang, E. S., Mozaffarian, D., Fendrick, A. M., & Kim, D. D. (2025) · JAMA Health Forum · doi:10.1001/jamahealthforum.2025.0905 · Cited by 43
Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist
Tall Bull, S., Nuffer, W., & Trujillo, J. M. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108332 · Cited by 43
Knop, F. K., Urva, S., Rettiganti, M., Benson, C. T., Roell, W. C., Mather, K. J., Haupt, A., & Pratt, E. J. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15875 · Cited by 41
Obesity pharmacotherapy: incretin action in the central nervous system
Boer, G. A., Hay, D. L., & Tups, A. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.11.001 · Cited by 52
Evidence for the contribution of the gut microbiome to obesity and its reversal
de Wit, D. F., Hanssen, N. M. J., Wortelboer, K., Herrema, H., Rampanelli, E., & Nieuwdorp, M. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg2773 · Cited by 51
“It is unlikely that microbiome-targeting therapies will outperform the current most effective therapies for obesity, bariatric surgery [~30% total body weight loss at 1-year follow-up ( 77 )] and incretin-based therapies such as tirzepatide [~20% total body weight loss in a 72-week trial; ( 89 )].”
BackgroundLüthi, H., Lengsfeld, S., Burkard, T., Meienberg, A., Jeanloz, N., Vukajlovic, T., Bologna, K., Steinmetz, M., Bathelt, C., Sailer, C. O., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102429 · Cited by 42
“23,24 44 Forth, sample size estimation was based on expected smoking abstinence rates at week 12 and not powered for outcomes such as smoking abstinence, weight change or HbA1c levels at week 24 or 52.”
BackgroundObesity: The Perfect Storm for Heart Failure
Lembo, M., Strisciuglio, T., Fonderico, C., Mancusi, C., Izzo, R., Trimarco, V., Bellis, A., Barbato, E., Esposito, G., Morisco, C., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14641 · Cited by 56
“166 Retatrutide is an agonist of the GIP, GLP-1, and glucagon receptors.”
BackgroundAbdelmalek, M. F., Harrison, S. A., & Sanyal, A. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15524 · Cited by 48
Psaltis, J. P., Marathe, J., Nguyen, M. T., Le, R., Bursill, C. A., Marathe, C. S., Nelson, A. J., & Psaltis, P. J. (2024) · Medicinal Research Reviews · doi:10.1002/med.22070 · Cited by 52
COHEN, R. V., Park, J. Y., Prager, G., Bueter, M., le Roux, C. W., Parmar, C. D., Kermansaravi, M., Salminen, P. T. P., & Miras, A. D. (2024) · British journal of surgery · doi:10.1093/bjs/znae284 · Cited by 50
Tirzepatide for overweight and obesity management
Hamza, M., Papamargaritis, D., & Davies, M. J. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2436595 · Cited by 43
“Key secondary end-points showed weight reductions of ≥ 10% in 63–70% of participants receiving tirzepatide versus 8.7% with placebo; ≥15% in 41–52% versus 2.6% with placebo; and ≥ 20% in 23– 34% versus 1% with placebo [48].”
InfluentialTheodorakis, N., & Nikolaou, M. (2025) · Biomedicines · doi:10.3390/biomedicines13010135 · Cited by 50
“SURMOUNT-1, along with its extension, thus established tirzepatide as a highly efficacious and potentially disease-modifying therapy in obesity and pre-diabetes, setting new benchmarks in long-term weight management and metabolic risk reduction [28].”
Structural pharmacology and mechanisms of GLP-1R signaling
Zhou, Q., Zhao, F., Zhang, Y., Yang, D., & Wang, M. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.03.003 · Cited by 53
Lam, C. S. P., Rodríguez, Á., Aminian, A., Ferrannini, E., Heerspink, H. J. L., Jastreboff, A. M., Laffin, L. J., Pandey, A., Ray, K. K., Ridker, P. M., et al. (2025) · Obesity · doi:10.1002/oby.24332 · Cited by 59
“Tirzepatide administered at the dose of 15 mg weekly demonstrates a mean weight reduction of 20.9% and 25.3% in participants with obesity or overweight, but without diabetes, in SURMOUNT-1 and SURMOUNT-4, respectively [19, 20].”
InfluentialSelf-citationO'Keefe, J. H., Franco, W. G., & O'Keefe, E. L. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.12.010 · Cited by 42
Beavers, K. M., Cortes, T. M., Foy, C. M., Dinkla, L., Reyes San Martin, F., Ard, J. D., Serra, M. C., & Beavers, D. P. (2025) · Obesity · doi:10.1002/oby.24172 · Cited by 41
“GLP1Ra-based treatment was also associated with significantly reduced LM (treatment effect difference: (cid:1) 1.9 kg; 95% CI: (cid:1) 3.5 to (cid:1) 0.2), on average, with study-specific treatment effects ranging from gains of 1.2 kg [19] to losses of 4.5 kg [7].”
InfluentialPharmacologic management of weight regain following bariatric surgery.
Lucas, E., Simmons, O., Tchang, B., & Aronne, L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1043595 · Cited by 41
“Pharmacotherapies with gut peptide modulators are emerging as the most effective AOMs (44, 45), with the most recent addition, tirzepatide 15 mg, demonstrating about 20% average weight loss, greater than lap band but less than sleeve gastrectomy and gastric bypass (38).”
BackgroundSelf-citationCamilleri, M., & Lupianez-Merly, C. (2024) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002519 · Cited by 41
Long-term Outcomes Following Adolescent Metabolic and Bariatric Surgery
Beamish, A. J., Harper, E. R., Järvholm, K., Janson, A., & Olbers, T. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad155 · Cited by 44
Gasbjerg, L. S., Rosenkilde, M. M., Meier, J. J., Holst, J. J., & Knop, F. K. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15216 · Cited by 41
“For all phase 2 17,18 and phase 3 studies of tirzepatide, 19 – 26 reported adverse events have been dominated by mild to moderate, transient, dose-dependent gastrointestinal effects (nausea, diarrhoea and vomiting), very similar to those observed during treatment with GLP-1 receptor agonists.”
BackgroundResultTirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence
Corrao, S., Pollicino, C., Maggio, D., Torres, A., & Argano, C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1402583 · Cited by 63
“TZP treatment was correlated with reduced systolic blood pressure (SBP), waist circumference, plasma lipid concentrations and fasting insulin (103).”
BackgroundSubhani, M., Dhanda, A., King, J. A., Warren, F. C., Creanor, S., Davies, M. J., Eldeghaidy, S., Bawden, S., Gowland, P. A., Bataller, R. A., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102920 · Cited by 57
Aminian, A., Aljabri, A., Wang, S. Z., Bena, J., Allende, D. S., Rosen, H., Arnold, E., Wilson, R. L., Milinovich, A., Loomba, R. S., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03480-y · Cited by 56
Crater, G. D., Lalonde, K., Ravenelle, F., Harvey, M., & Després, J. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15353 · Cited by 41
Madsbad, S., & Holst, J. J. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2472408 · Cited by 43
“In SURMOUNT 1, 2539 participants were randomized to tirzepatide 5, 10, 15 mg once weekly for 72 weeks, including a 20-week dose escalating period [82].”
GLP-1 and the Neurobiology of Eating Control: Recent Advances
Jones, L. A., & Brierley, D. I. (2025) · Endocrinology · doi:10.1210/endocr/bqae167 · Cited by 43
“The loss of lean body mass is another common side effect of GLP-1RAs, with studies reporting that lean mass loss accounts for ∼ 45% and ∼ 25% of total loss for semaglutide (79, 105) and tirzepatide (98), respectively.”
Incretin-based investigational therapies for the treatment of MASLD/MASH
Brouwers, B., Rao, G., Tang, Y., Rodríguez, Á., Glass, L. C., & Hartman, M. L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111675 · Cited by 40
Bashir, B., Schofield, J., Downie, P., France, M., Ashcroft, D. M., Wright, A. K., Romeo, S., Gouni-Berthold, I., Maan, A., Durrington, P. N., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1389106 · Cited by 40
Obesity and asthma: A focused review
Tooba, R., & Wu, T. D. (2022) · Respiratory Medicine · doi:10.1016/j.rmed.2022.107012 · Cited by 54
Weight-centric treatment of type 2 diabetes mellitus
Ghusn, W., Hurtado, M. D., & Acosta, A. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100045 · Cited by 40
“In an RCT evaluating this medication, the TBWL % associated with tirzepatide 5 mg was 15.0%, tirzepatide 10 mg was 15.9%, and tirzepatide 15 mg was 20.9% (p 0.001 for all comparisons with placebo) [100].”
BackgroundInfluentialAzuri, J., Hammerman, A., Aboalhasan, E., Sluckis, B., & Arbel, R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14940 · Cited by 40
“High doses of the glucagon-like peptide-1 agonist (GLP-1RA) semaglutide and the dual glucose-dependent insulinotropic polypeptide and GLP-1RA tirzepatide have significantly reduced weight in patients with T2DM in STEP 1 and SURMOUNT-1 trials, with a follow-up of 68 and 72 weeks, respectively.(10,11) Although obesity-a…”
BackgroundSevere hypertriglyceridemia: Existing and emerging therapies
Malick, W. A., Do, R., & Rosenson, R. S. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108544 · Cited by 40
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.